Kevan Clifford Herold MD

Diabetes, Lipid Metabolism

Professor, Immunobiology, Yale University School of Medicine

789 Howard Avenue 2nd FloorDana BuildingNew Haven, CT 06510

Dr. Herold is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Herold's full profile Already have an account?

Education & Training

University of ChicagoFellowship, Endocrinology, Diabetes, and Metabolism, 1982 - 1986
Temple University HospitalResidency, Internal Medicine, 1979 - 1982
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1979

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

NY State Medical License 1998 - 2027
CT State Medical License 2006 - 2026
IL State Medical License 1982 - 1999
PA State Medical License 1981 - 1986
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Endocrinology, Diabetes and Metabolism

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2015-2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2015-2017

Clinical Trials

TrialNet Pathway to Prevention of T1D Start of enrollment: 2004 Feb 01
RECRUITING
Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes
COMPLETED
PHASE2
Anti-CD3 mAb Treatment of Recent Onset Type 1 Diabetes
COMPLETED
PHASE2

Publications & Presentations

PubMed

Islet Autoantibody Patterns Vary by Race and Ethnicity and Area Deprivation Index for Individuals at Risk for Type 1 Diabetes.
Ananta Addala, Susanne Cabrera, David Cuthbertson, Ingrid Libman, Mustafa Tosur
Diabetes Care. 2026-08-07
A surviving beta cell subpopulation enriched in patients with T1D.
Maxwell Spurrell, John S Tsang, Kevan C Herold
Biorxiv. 2026-05-27
New and emerging therapies in type 1 diabetes mellitus.
Kevan C Herold, Carmella Evans-Molina
The Journal of Clinical Investigation. 2026-05-15

Journal Articles

A Call for Improved Reporting of Human Islet Characteristics in Research Articles
Steven E Kahn, Kevan C Herold, Maureen Gannon, Diabetologia
Identification and Analysis of Islet Antigen–Specific CD8+ T Cells with T Cell Libraries
Kevan C Herold, Andrea K Steck, The Journal of Immunology
Reprogramming Human T Cell Function and Specificity with Non-Viral Genome Targeting
Neil Romberg, Antoni Ribas, Michael R Lee, Ruby Yu, Gary M Kupfer, Julia Carnevale, Jonathan H Esensten, P Jonathan Li, Han Li, Kevan C Herold, Alexander Marson, Nature

Lectures

Abnormal Neutrophil Signature in the Blood and Pancreas of Presymptomatic and Symptomatic Type 1 Diabetes
New Haven, CT - 6/15/2014

Press Mentions

YSM Expert Available to Discuss Stem Cell-Derived Islets for Type 1 DiabetesSeptember 5th, 2025
How Immune Checkpoint Inhibitors Can Induce DiabetesJuly 1st, 2025
Nektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients with New Onset Type 1 Diabetes MellitusFebruary 24th, 2025